Literature DB >> 27163989

Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.

Ole J Storebø1, Erik Simonsen2, Christian Gluud3.   

Abstract

CLINICAL QUESTION: Is treatment with methylphenidate associated with benefits or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)? BOTTOM LINE: Methylphenidate is associated with improvement in ADHD symptoms, general behavior, and quality of life; however, due to the very low quality of the evidence, the magnitude of the associated improvement is uncertain. Methylphenidate was associated with an increased risk of nonserious adverse events. There are too few data to assess the association with serious adverse events.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27163989     DOI: 10.1001/jama.2016.3611

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

1.  Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.

Authors:  Nicholas King; Samuel Floren; Natasha Kharas; Ming Thomas; Nachum Dafny
Journal:  Pharmacol Biochem Behav       Date:  2019-06-19       Impact factor: 3.533

Review 2.  Selectivity of probes for PET imaging of dopamine D3 receptors.

Authors:  Robert K Doot; Jacob G Dubroff; Kyle J Labban; Robert H Mach
Journal:  Neurosci Lett       Date:  2018-03-05       Impact factor: 3.046

3.  Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate Adverse Effects in a Randomized Trial of Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Tanya E Froehlich; William B Brinkman; James L Peugh; Alexandra N Piedra; Daniel J Vitucci; Jeffery N Epstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-12-16       Impact factor: 2.576

4.  ADHD Medication and Substance-Related Problems.

Authors:  Patrick D Quinn; Zheng Chang; Kwan Hur; Robert D Gibbons; Benjamin B Lahey; Martin E Rickert; Arvid Sjölander; Paul Lichtenstein; Henrik Larsson; Brian M D'Onofrio
Journal:  Am J Psychiatry       Date:  2017-06-29       Impact factor: 18.112

5.  Psychotropic Medication Use by Children with Autism Served in Publicly Funded Mental Health Settings.

Authors:  Barbara Caplan; Colby Chlebowski; Gina May; Mary J Baker-Ericzén; Willard Connor; Lauren Brookman-Frazee
Journal:  J Dev Behav Pediatr       Date:  2021-11-30       Impact factor: 2.988

6.  Racial and Ethnic Differences in ADHD Treatment Quality Among Medicaid-Enrolled Youth.

Authors:  Janet R Cummings; Xu Ji; Lindsay Allen; Cathy Lally; Benjamin G Druss
Journal:  Pediatrics       Date:  2017-05-16       Impact factor: 7.124

Review 7.  Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.

Authors:  Mathilde Holmskov; Ole Jakob Storebø; Carlos R Moreira-Maia; Erica Ramstad; Frederik Løgstrup Magnusson; Helle B Krogh; Camilla Groth; Donna Gillies; Morris Zwi; Maria Skoog; Christian Gluud; Erik Simonsen
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

8.  Effects of Methylphenidate on Cognitive Function in Adults with Traumatic Brain Injury: A Meta-Analysis.

Authors:  Yung-Jiun Chien; Yung-Chen Chien; Chien-Ting Liu; Hsin-Chi Wu; Chun-Yu Chang; Meng-Yu Wu
Journal:  Brain Sci       Date:  2019-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.